Palvellatx

Wayne, US · 2 known investors

Palvella Therapeutics is a biotechnology company developing topical treatments for rare genetic skin diseases that lack approved therapies, based on its QTORIN drug delivery platform. Its lead candidate, QTORIN rapamycin gel, is in clinical development for microcystic lymphatic malformations and other mTOR-driven dermatologic conditions.